Timely diagnosis and subsequent management of Multiple Myeloma avoids complications that impact patients’ quality of life. Earlier diagnosis and therefore commencement of treatment significantly improves 5-year survival rates of patients.
Primary care providers therefore play a key role in recognizing and ruling out Multiple Myeloma at the earlier stages of the disease.
Professor Andrew Spencer
Head of Malignant Haematology, Stem Cell Transplantation and Head of Myeloma Research at The Alfred Hospital, Australia
Multiple Myeloma symptoms are non-specific and may mimic the aging process or more common conditions encountered at primary care, such as diabetes, hypertension and cardiac disease4.
Patients often present at primary care with bone pain, back pain, aches and generally feeling unwell.
When symptoms are unexplained or persist despite intervention, look out for one or more early warning signs of Multiple Myeloma4.
As Multiple Myeloma progresses, advanced presentations are associated with end-organ damage. These are referred to as CRAB events of Multiple Myeloma and include hypercalcemia, renal impairment, anaemia, and bone lesions.
A number of blood tests are recommended to rule out Multiple Myeloma, as highlighted in the publication by Dr Joseph Mikhael, MD and Chief Medical Officer, International Myeloma Foundation4. This includes—although not limited to—the following:
Adapted from:
Seesaghur A et al. Clinical features and diagnosis of multiple myeloma: a population-based cohort study in primary care. BMJ Open 20213
When the patient symptoms and basic laboratory findings are suggestive of Multiple Myeloma, assessment of serum protein studies will help to rule out Multiple Myeloma4.
The survival rate for Multiple Myeloma patients is increased by over one and a half times when the diagnosis is achieved through the primary care referral pathway- rather that the emergency route5.
As the gatekeepers to earlier diagnosis of Multiple Myeloma, primary care practitioners should be alert to the early warning signs. Requesting the best test combination to rule out Multiple Myeloma earlier, allows for a timelier referral pathway to hematology.
Adapted from:
Myeloma: Diagnosis and management. NICE Guidelines 2016
The products referred to on this page may differ from what is commercially available in your country. To find out what is available in your country, please contact your local Binding Site representative.
Not for use in China.